Giant Biogene Holding Co Ltd is a China-based investment holding company. The Company is principally engaged the research, development, manufacture and sale of bioactive material-based beauty and health products through its subsidiaries. The Company's main products include functional skincare products and medical dressings, and they are produced with recombinant collagen as the key bioactive ingredient. The Company also develops and manufactures rare ginsenosides technology-based functional foods. The Company mainly conducts its businesses within the domestic market.

Employees

1,512

Sector

Personal Products

Calendar

30/03/2025 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
17/09/24	35.75 $	+0.14%	713,200
16/09/24	35.70 $	-1.38%	645,750
13/09/24	36.20 $	+1.40%	3,522,762
12/09/24	35.70 $	-7.51%	8,337,200
11/09/24	38.60 $	-1.66%	2,562,000

Delayed Quote Hong Kong S.E., September 17, 2024 at 09:08 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

18

Last Close Price

35.75HKD

Average target price

56.76HKD

Spread / Average Target

+58.78%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 09:08:15 17/09/2024 BST			5-day change	1st Jan Change
35.75 ^HKD	+0.14%		-8.92%	+0.42%

08-23	Certain Ordinary Shares of Giant Biogene Holding Co., Ltd. are subject to a Lock-Up Agreement Ending on 23-AUG-2024.	CI
08-19	Giant Biogene Holding Records 47% Higher Profit in H1	MT

Capitalization	32.85B 4.64B 36.15B 351B	P/E ratio 2024 *	16.9x	P/E ratio 2025 *	13.4x
Enterprise value	29.17B 4.12B 32.1B 312B	EV / Sales 2024 *	5.62x	EV / Sales 2025 *	4.06x
Free-Float	42.68%	Yield 2024 *	1.81%	Yield 2025 *	2.28%

Certain Ordinary Shares of Giant Biogene Holding Co., Ltd. are subject to a Lock-Up Agreement Ending on 23-AUG-2024.	08-22	CI
Giant Biogene Holding Records 47% Higher Profit in H1	08-19	MT
Giant Biogene Holding Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-19	CI
Giant Biogene Launches New Brand Vpro Featuring Vlock 4D Recombinant Collagen for Cellular Anti-Aging	07-04	CI
Giant Biogene Holding Co., Ltd. Approves Payment of Special Dividend, Payable on July 5, 2024	06-13	CI
Giant Biogene Holding Co., Ltd. Approves Payment of Final Dividend , Payable on July 5, 2024	06-13	CI
Giant Biogene Places 33.2 Million Shares for About HK$1.63	05-27	MT
Giant Biogene’s Profit Up 47% in 2023	04-30	MT
Giant Biogene to Pay Special 0.45 Yuan per Share Dividend	03-26	MT
Giant Biogene Holding Co., Ltd. Proposes Special Cash Dividend for the Year Ended 31 December 2023, Payable on 05 July 2024	03-25	CI
Giant Biogene Holding Co., Ltd. Proposes Final Ordinary Cash Dividend for the Year Ended 31 December 2023, Payable on 05 July 2024	03-25	CI
Giant Biogene Holding Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Certain Ordinary Shares of Giant Biogene Holding Co., Ltd. are subject to a Lock-Up Agreement Ending on 3-NOV-2023.	11-02	CI

Descubrimiento: Cuatro empresas en el mundo del deporte	11-30
Découverte : quatre entreprises dans le monde du sport	11-30

Giant Biogene Holding Co., Ltd. Share Price

Equities

2367

KYG3887G1091

Personal Products

Valuation: Giant Biogene Holding Co., Ltd.

Chart: Giant Biogene Holding Co., Ltd.

Latest news: Giant Biogene Holding Co., Ltd.

News in other languages: Giant Biogene Holding Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Giant Biogene Holding Co., Ltd.

Other Personal Products

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	+0.14%
1 week	-8.92%
Current month	-13.33%
1 month	-10.51%
3 months	-22.70%
6 months	-13.86%
Current year	+0.42%

Director	Title	Age	Since
Jian Ya Yan CEO	Chief Executive Officer	57	30/04/00
Hui Juan Zhang DFI	Director of Finance/CFO	37	-
Yu Bo Yan BRD	Director/Board Member	28	30/09/18

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GIANT BIOGENE HOLDING CO., LTD.	+0.14%	-8.92%	+1.27%	-	4.63B
PROCTER & GAMBLE COMPANY	-1.11%	-2.18%	+13.33%	+20.49%	413B
UNILEVER PLC	-1.20%	-2.44%	+18.87%	+24.50%	162B
COLGATE-PALMOLIVE COMPANY	-1.32%	-3.43%	+41.01%	+35.35%	85.43B
HINDUSTAN UNILEVER LIMITED	+0.10%	-0.76%	+16.46%	+5.71%	80.59B
KENVUE INC.	-0.86%	+0.61%	+9.28%	-	44.8B
ESTEE LAUDER	-0.11%	+3.37%	-43.48%	-72.49%	31.6B
BEIERSDORF	-1.19%	-2.36%	+1.55%	+20.17%	31.33B
ESSITY AB	-0.81%	-1.00%	+30.41%	+18.25%	21.9B
GODREJ CONSUMER PRODUCTS LIMITED	-1.87%	-4.72%	+42.92%	+31.32%	17.82B
Average	-0.62%	-1.30%	+13.16%	+10.41%	89.31B
Weighted average by Cap.	-0.04%	-0.90%	+15.58%	+18.03%

	2024 *	2025 *
Net sales	5.11B 721M 5.62B 54.57B	6.69B 944M 7.36B 71.45B
Net income	1.97B 279M 2.17B 21.1B	2.5B 354M 2.76B 26.75B
Net Debt	-4.17B -588M -4.58B -44.51B	-5.7B -805M -6.27B -60.88B